Wedbush Raises Price Target on Boston Scientific (BSX) to $25 Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Notable 52-Week Highs and Lows 7/28: (FB) (BSX) (GRUB) High; (INFN) (PRLB) (MVIS) Low
July 28, 2016 3:34 PM EDT52-Week High:Facebook (Nasdaq: FB) $128.33. Facebook reported Q2 adjusted EPS of $0.97, versus the analyst estimate of $0.82. Revenue for the quarter came in at $6.44 billion versus the consensus estimate of $6.02 billion. Mobile MAUs were 1.57 billion as of June 30, 2016, an increase of 20% year-over-year.
Boston Scientific (NYSE: BSX) $24.79. Boston Scientific reported Q2 EPS of $0.27, in-line with the analyst estimate of $0.27. Revenue for the quarter came in at... More
Boston Scientific (BSX) PT Raised to $28 at Needham & Company
July 28, 2016 2:38 PM EDTNeedham & Company analyst Mike Matson reiterated a Buy rating and bumped his price target on Boston Scientific (NYSE: BSX) to $28.00 (from $26.00) following doubled-digit organic growth in Q2.
Matson commented, "BSX beat consensus 2Q16 revenue and met consensus EPS. BSX's organic constant currency... More
Boston Scientific (BSX) PT Bumped to $26 at Evercore ISI
July 28, 2016 12:46 PM EDTEvercore ISI analyst Vijay Kumar reiterated a Buy rating and lifted his price target on Boston Scientific (NYSE: BSX) to $26.00 (from $25.50) following results this morning.
The firm maintained FY 2016 EPS of $1.11, FY 2017 EPS of $1.30 and raised FY 2018 EPS from $1.52 to $1.55.
Kumar commented, "Just when investors sighed a breath of relief after last Q when the long awaited new product momentum drove a... More
Boston Scientific (BSX) Reports In-Line Q2 EPS; Bumps FY16 Rev View
July 28, 2016 6:34 AM EDTBoston Scientific (NYSE: BSX) reported Q2 EPS of $0.27, in-line with the analyst estimate of $0.27. Revenue for the quarter came in at $2.13 billion versus the consensus estimate of $2.05 billion.
"Our strong performance is evidence of the success of our category leadership strategy," said Mike... More
Trading Radar for 7/28: Alphabet (GOOG), Amazon (AMZN), Ford (F), Baidu (BIDU), MasterCard (MA) Report
July 27, 2016 2:49 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
ACI Worldwide, Inc. (Nasdaq: ACIW) - consensus loss $0.04
ARIAD Pharma (Nasdaq: ARIA) - consensus loss $0.11
Acorda Therapeutics (Nasdaq: ACOR) - consensus EPS $0.18
Agenus (Nasdaq: AGEN) - consensus... More
Boston Scientific (BSX) Acquires RFA Systems Makter Cosman Medical
July 27, 2016 9:02 AM EDTBoston Scientific Corporation (NYSE: BSX) announced that it has acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer of radiofrequency ablation (RFA) systems. The Cosman Medical team and products will become part of the Boston Scientific Neuromodulation business, which offers a range of Spinal Cord Stimulator (SCS) systems to treat patients with chronic pain, and Deep Brain Stimulation systems* for the treatment of Parkinson's disease, dystonia and essential tremor.
"This acquisition is a natural extension of our current product portfolio and will help us provide physicians and patients more options to address chronic... More
